Leaked letters show AstraZeneca vaccine commitment not as Thailand claimed

By Panu Wongcha-um

BANGKOK, July 19 (Reuters) - AstraZeneca Plc AZN.L has told Thailand it should be able to supply around 6 million doses of its COVID-19 vaccine per month, leaked correspondence showed, contradicting assertions by Thai officials that the government is owed 10 million.

Thailand's push for 10 million monthly doses comes as it considers imposing vaccine export curbs on Thai-manufactured vaccines to shore up domestic supplies, a move that could create problems for its neighbours, some of which are battling similar or more severe coronavirus crises.

But a June 25 letter by AstraZeneca to Thailand's health minister showed that the Anglo-Swedish drugmaker had offered to supply just 5-6 million doses a month to Thailand from a local plant, or one third of the amount produced by its partner Siam Bioscience, which is owned by Thailand's king.

"I hope you will be pleased that this is nearly twice the volume we discussed during our meeting," AstraZeneca's vice president of global corporate affairs, Sjoerd Hubben, said in the letter, referring to a September 2020 meeting with Thai officials.

At that meeting, Thai government officials estimated Thailand required around 3 million doses per month, Hubben wrote.

The correspondence was first reported by Isara news agency and later seen by Reuters.

The idea of Thailand limiting exports of locally produced vaccines first surfaced last week as the country suffers a crushing new wave of the coronavirus, with record numbers of cases several days in a row.

Thailand has inoculated just 5.2% of its population of more than 66 million so far.

Deputy Health Minister Sathit Pitutacha said last week that AstraZeneca had requested delays to the 61 million doses he said the company had promised to Thailand by the end of 2021. That commitment would have allowed Thailand to administer 10 million doses per month this year, he said.

"We want 10 million doses because the original plan was 10 million doses," Sathit said.

A source with knowledge of Thailand's AstraZeneca agreement said the 61 million doses, about a third of the local factory's agreed output, would be delivered to Thailand overall, but no monthly volume commitment had ever been agreed. Reuters has not viewed the full agreement.

The director-General of the Thai Disease Control Department, Opas Karnkawinpong, confirmed on Sunday that the June 25 letter was authentic. He told reporters the 3 million figure had been a rough estimate and Thailand had formally asked AstraZeneca in April 2021 to provide 10 million monthly doses.

He did not say whether AstraZeneca had agreed to that, and said it was understood that vaccine availability depended on output and volume might need to be agreed on a monthly basis.

AstraZeneca had no comment on Monday on the leaked letter.

The letter also detailed AstraZeneca's supply commitments of nearly 114 million doses elsewhere in Asia - a supply chain that has become uncertain due to potential export restrictions by the Thai government.

It planned to supply 50 million doses to Indonesia, 30 million to Vietnam, 16.5 million to the Philippines, 10 million to Taiwan and 6.4 million to Malaysia, the letter showed.

Opposition lawmaker Wiroj Lakkhanaadisorn said Thai authorities were prepared for neither a global supply shortage nor the severe impact of variants of concern.

"The government was over-confident about the situation when making these plans," he told Reuters on Monday. "They have been very slow and careless."
Writing by Martin Petty; Editing by Mark Heinrich and Jane Wardell

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。


本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

我們運用 cookies 提供您最佳之網頁使用經驗。更改您的cookie 設定跟詳情。

風險提示: 您的資金存在風險。杠杆商品可能不適合所有客戶。 請詳細閱讀我們的風險聲明